期刊
MOLECULAR THERAPY
卷 18, 期 6, 页码 1123-1129出版社
CELL PRESS
DOI: 10.1038/mt.2010.67
关键词
-
资金
- Fonds de Recherche en Sante du Quebec
- Canadian Institutes of Health Research
- Ontario Institute for Cancer Research
Oncolytic viruses (OVs) are promising anticancer agents but like other cancer monotherapies, the genetic heterogeneity of human malignancies can lead to treatment resistance. We used a virus/cell-based assay to screen diverse chemical libraries to identify small molecules that could act in synergy with OVs to destroy tumor cells that resist viral infection. Several molecules were identified that aid in viral oncolysis, enhancing virus replication and spread as much as 1,000-fold in tumor cells. One of these molecules we named virus-sensitizers 1 (VSe1), was found to target tumor innate immune response and could enhance OV efficacy in animal tumor models and within primary human tumor explants while remaining benign to normal tissues. We believe this is the first example of a virus/cell-based pharmacoviral screen aimed to identify small molecules that modulate cellular response to virus infection and enhance oncolytic viro-therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据